Showing results (251-260 of 322) with videos related to
Sort By:
Pageof 33
Blood|January 21, 2014
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohortsFrancesco Passamonti, Margherita Maffioli, Francisco Cervantes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary MyelofibrosisPaola Guglielmelli, Terra L Lasho, Giada Rotunno, et al.The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.Blood|November 7, 2012
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutationVittorio Rosti, Laura Villani, Roberta Riboni, et al.Blood|January 13, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti, Chiara Elena, Susanne Schnittger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.Therapeutic Advances in Hematology|September 15, 2022
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to 9/L) at baseline: the final analysis of EXPANDPaola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.Blood|March 24, 2007
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaAlessandro M Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, et al.Pageof 33